Skip to content
Wanbury logo

Wanbury

WANBURY NSE
₹174.16 1.86 (1.06%)
Market Cap
₹609 Cr
P/E
10.88

Wanbury (WANBURY) share price was ₹174.16 at the 28 Oct 2026 close; market capitalisation ₹609 Cr; P/E (TTM) 10.88; sector Healthcare. The share price fell 32.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 1.5% year on year to ₹165.58 Cr and net profit fell 76.0% year on year to ₹3.24 Cr (compared with Jun 2025). Promoters held 42.98% of Wanbury in Sep 2026, down 0.04 percentage points from Jun 2026. Its Tapetide Score is 40/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹174.16 −82.09 −32.04% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹609 Cr
P/E (TTM)
10.88
EBITDA
₹79.80 Cr
Return on Equity
51.51%
Debt to Equity
1.56
Book Value
₹41.32
EPS (TTM)
₹16.01
52W High
₹358.85
52W Low
₹161.50

Price-based figures as of 28 Oct 2026, 15:51 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Wanbury (this company)
₹174.1610.88609 Cr4.210.00%51.51%27.79%634 Cr56 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.47%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
40 Weak
Overall score
Data confidence 98/100

Category scores

Quality Good 56
Returns, margins, earnings quality 22%
Valuation Average 55
Cheap vs sector & own history 24%
Growth Poor 19
Sales & profit trajectory 9%
Financial Health Poor 17
Solvency, leverage, coverage 9%
Momentum Poor 15
Trend strength, vol-adjusted 12%
Ownership Poor 35
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 47.8% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 82.2%

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 10.6% over past five years.
  • Tax rate seems low
  • Promoters have pledged 62.2% of their holding.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

BearishNeutralBullish

Bearish

Bearish
13
Neutral
5
Bullish
1

Moving Averages

BearishNeutralBullish

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
4.22% lower than 3Y

change over 1 year

Net Income Growth
-45.54% lower than 3Y

change over 1 year

Cash Flow Change
556%

change over 1 year

EBITDA Margin Change
5%

change over 1 year Operating margin 9.8% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
146
144
146
139
131
161
133
172
163
160
162
165
166
Expenses
133
127
124
121
120
141
120
142
139
134
136
135
149
Operating Profit
13.35
17.34
21.15
18.16
10.98
20.01
13.95
29.63
24.44
25.78
26.68
29.84
16.23
OPM %
9.13%
12%
14.54%
13.03%
8.37%
12.41%
10.45%
17.23%
14.98%
16.11%
16.42%
18.13%
9.8%
Other Income
0.62
0.76
0.69
0.93
0.94
1.63
0.84
1.84
0.35
0.2
0.18
-3.39
0.36
Interest
5.79
7.67
8.26
7.46
7.59
10.15
10.17
9.04
7.54
7.12
7.26
8.06
7.97
Depreciation
3.18
3.24
3.32
3.28
3.29
3.32
3.32
3.37
3.64
3.7
3.74
3.23
4.04
PBT
5
7.19
10.26
8.35
1.04
8.17
1.3
19.06
13.61
15.16
15.86
15.16
4.58
Tax %
6%
-2.5%
-0.19%
3.23%
0%
1.84%
5.38%
-6.3%
0.88%
-0.13%
0.69%
-43.14%
29.26%
Net Profit
4.69
7.36
10.27
8.08
1.04
8.02
1.22
20.26
13.49
15.18
15.76
21.7
3.24
EPS (₹)
1.43
2.25
3.14
2.47
0.32
2.45
0.37
6.18
4.1
4.35
4.52
6.21
0.93
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
250
420
432
370
391
367
392
511
500
578
600
650
653
Expenses
228
387
414
438
375
344
374
475
476
506
523
544
554
Operating Profit
21
34
19
-68
16
23
18
36
23
72
77
107
99
OPM %
9%
8%
4.3%
-18%
4.1%
6%
4.7%
7%
4.7%
12%
13%
16%
15%
Other Income
6
0
90
76
9
84
2
77
0
1
3
-3
-3
Interest
19
32
36
31
40
33
23
21
21
29
37
30
30
Depreciation
5
9
10
10
10
10
10
11
12
13
13
14
15
PBT
4
-7
62
-32
-25
65
-12
81
-10
31
30
60
51
Tax %
28%
0%
1%
-1%
-1%
0%
2%
0%
1%
1%
-3%
-11%
—
Net Profit
3
-7
62
-32
-25
64
-13
81
-10
30
31
66
56
EPS (₹)
1.61
-3.52
26.71
-13.49
-10.48
25.79
-5.04
24.94
-3.18
9.28
9.32
18.93
16.01
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
20
20
23
24
24
25
25
33
33
33
33
35
Reserves
-188
-183
-151
-183
-207
-143
-156
-30
-40
-5
26
110
Borrowings
381
373
273
224
233
164
166
74
68
116
179
226
Other Liabilities
182
176
265
207
235
231
253
275
241
199
176
147
Total Liabilities
394
386
411
271
285
277
288
351
302
343
414
518
Fixed Assets
164
180
186
178
172
164
167
167
167
167
201
229
CWIP
19
14
10
10
9
14
11
2
2
3
5
25
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
212
192
215
83
103
99
109
182
133
173
208
263
Total Assets
394
386
411
271
285
277
288
351
302
343
414
518
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
40
43
43
32
30
44
17
41
20
5
26
32
Investing
-5
-20
-13
-1
-3
64
8
1
-9
-17
-51
-56
Financing
-30
-28
-27
-33
-27
-108
-17
-29
-32
14
26
22
Net Cash Flow
5
-5
3
-2
0
0
7
13
-21
2
1
-2
Free Cash Flow
35
22
29
30
25
36
12
42
7
-9
-22
-28
CFO/OP
187
129
234
-49
188
188
97
113
86
7
35
30
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
144
65
71
29
41
50
32
45
50
56
70
80
Inventory Days
103
69
63
27
36
25
41
60
26
43
47
67
Days Payable
300
171
259
173
208
252
220
218
178
196
172
142
Cash Conversion Cycle
-54
-37
-124
-117
-131
-176
-147
-112
-101
-96
-55
6
Working Capital Days
-139
-123
-164
-251
-230
-211
-227
-134
-129
-37
3
17
ROCE %
—
12%
55%
-1%
26%
31%
23%
46%
17%
58%
34%
31%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Wanbury insights

67 extracted metrics + investor summaries across FY08–FY27.

Shareholding Pattern

DIIs0.02%Promot.42.98%FIIs0.71%Others14.28%Public42.00%As ofSep 2026
5.49% of promoter holding pledged as of Sep 2026

Documents

Frequently Asked Questions about Wanbury

What does Wanbury Ltd do?
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
Where is Wanbury Ltd (WANBURY) listed?
Wanbury Ltd trades as WANBURY on the NSE and under code 524212 on the BSE.
Which sector does Wanbury Ltd belong to?
Wanbury Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Wanbury Ltd?
Wanbury Ltd has a market capitalisation of ₹608.98 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Wanbury Ltd?
Wanbury Ltd trades at a PE ratio of 10.88 as of 28 Oct 2026, on earnings per share of ₹16.01, against a book value of ₹41.32 per share.
What is the 52-week high and low of Wanbury Ltd?
Over the last 52 weeks Wanbury Ltd has traded between ₹161.5 and ₹358.85 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Wanbury Ltd?
Wanbury Ltd reported a return on equity of 51.51%. Its debt-to-equity ratio is 1.56.

Company Information

Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]

Website wanbury.com
CEO Mr. Mohan Kumar Rayana
Employees 1,382
Listed 2007-01-29
Face Value ₹ 10
Shares Outstanding 3,49,66,928

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/WANBURY.md for Wanbury Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month